(champions oncology) (sbir topic 355) (direct to phase II) to address the slow growth rate of prostate pdxs by eliminating logistical barriers through development of CDX (i.e., PDX from circulating…
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201700013C
- Awardee
-
Champions Oncology, Inc. UEI K7EZES58U9N8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,999,931
Award facts
- Opportunity
-
- PHS20171OMINBUS Solicitation number
- Contract value 100% obligated
- $1,999,931.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 8 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Hackensack, NJ 07601, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $1,999,931 |
About this award
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Champions Oncology, Inc. The $1,999,931.00 Firm Fixed Price contract is for the development of CDX (circulating tumor cell-derived xenograft) models to address the slow growth rate of prostate patient-derived xenografts (PDXs). The period of performance is from September 19, 2017 to September 18, 2019, with an ultimate completion date of March 18, 2020. This contract is a direct-to-Phase II SBIR award, which indicates the project has already completed the Phase I feasibility study.
Description
(champions oncology) (sbir topic 355) (direct to phase II) to address the slow growth rate of prostate pdxs by eliminating logistical barriers through development of CDX (i.e., PDX from circulating tumor cells) models. Period of performance: 09/19/2017 - 09/18/2019
Quick answers
Who was awarded contract HHSN261201700013C?
HHSN261201700013C was awarded to Champions Oncology, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2017.
How much is contract HHSN261201700013C worth?
The government has obligated $1,999,931 on HHSN261201700013C.
Was contract HHSN261201700013C competed?
The extent of competition for HHSN261201700013C was full and open competition after exclusion of sources. The government received 8 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award